Mylan Laboratories has received final approval to manufacture and market terazosin HCI capsules in 1 mg, 2 mg, 5 mg and 10 mg strengths. Terazosin is the generic equivalent to Hytrin, an alpha-1-selective adrenoceptor blocking agent manufactured and marketed by Abbott Laboratories Inc.
The product is indicated for the treatment of symptomatic benign prostatic hyperplasia. It also is indicated for the treatment of hypertension and had sales of $425 million in 1999, according to Warburg Dillon Read analyst David Moskowitz, who noted, "This launch highlights the beginning of a large wave of generic opportunities, for which Mylan should be a leading beneficiary."
Mylan also has been shipping hydrochlorothiazide capsules, 12.5 mg, an approval the company received at the end of January. The product is the generic equivalent to Watson's Microzide, an antihypertensive.
COPYRIGHT 2000 Lebhar-Friedman, Inc.
COPYRIGHT 2000 Gale Group
Contact
Home
A
Habitrol